Bispecific Antibodies for Multiple Myeloma: Six Things to Know
In 2022, the drug teclistamab became the first bispecific antibody to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. Experts say the drug represents one of the most important advances in recent years against myeloma, a blood cancer diagnosed in more than 35,000 people in the United … Read more